Spinal muscular atrophy and therapeutic prospects

B Wirth, L Brichta, E Hahnen - Alternative Splicing and Disease, 2006 - Springer
B Wirth, L Brichta, E Hahnen
Alternative Splicing and Disease, 2006Springer
The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive
neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1).
The SMN2 gene, a nearly identical copy of SMN1, has been detected as a promising target
for SMA therapy. Both genes are ubiquitously expressed and encode identical proteins, but
markedly differ in their splicing patterns: While SMN1 produces full-length (FL)-SMN
transcripts only, the majority of SMN2 transcripts lacks exon 7. Transcriptional SMN2 …
Abstract
The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1). The SMN2 gene, a nearly identical copy of SMN1, has been detected as a promising target for SMA therapy. Both genes are ubiquitously expressed and encode identical proteins, but markedly differ in their splicing patterns: While SMN1 produces full-length (FL)-SMN transcripts only, the majority of SMN2 transcripts lacks exon 7. Transcriptional SMN2 activation or modulation of its splicing pattern to increase FL-SMN levels is believed to be clinically beneficial and therefore a crucial challenge in SMA research. Drugs such as valproic acid, phenylbutyrate, sodium butyrate, M344 and SAHA that mainly act as histone deacetylase inhibitors can mediate both: they stimulate the SMN2 gene transcription and/or restore the splicing pattern, thereby elevating the levels of FL-SMN2 protein. Preliminary phase II clinical trials and individual experimental curative approaches SMA patients show promising results. However, phase III double-blind placebo controlled clinical trials have to finally prove the efficacy of these drugs.
Springer